Deals channel feed

Al­ler­gan chief snaps up a ri­val biotech for $195M in cash, plus. Deal beefs up the aes­thet­ics pipeline

7 years ago

Su­per­nus bags ear­ly-stage CNS drug for $15M up­front in re­newed epilep­sy R&D ef­forts

7 years ago

Take­da starts to as­sem­ble a list of prod­ucts it plans to auc­tion off af­ter Shire buy­out — re­port

7 years ago

Boehringer In­gel­heim joins the crowd and goes all-in on on­colyt­ic virus­es, buy­ing Vi­raTher­a­peu­tics in $244M deal

7 years ago

Take­da shut­ter­ing Chica­go com­plex with 1,000 staffers in lead-up to Shire merg­er

7 years ago

Tra­di­tion­al­ists at Take­da spark a fam­i­ly feud with CEO Christophe We­ber over his $62B Shire takeover deal

7 years ago

No­vo Nordisk buys uni­ver­si­ty spin­out Ziy­lo — adding a po­ten­tial rem­e­dy for hy­po­glycemia to its di­a­betes pipeline

7 years ago

Astel­las grabs a biotech tod­dler in $109M buy­out deal for a glau­co­ma gene ther­a­py pro­gram

7 years ago
Cell/Gene Tx

Once a multi­bil­lion dol­lar com­pa­ny, Ova­Science ends a pen­ny­s­tock ve­hi­cle for Mil­len­do's re­verse merg­er

7 years ago

With high ex­pec­ta­tions on Provenge, Den­dreon is 'sol­d' (again) in $832M deal

7 years ago

Game change: Pfiz­er dou­bles down on its late-stage pipeline as CEO Read dis­avows a long re­liance on M&A deals

7 years ago
R&D

Would Ab­b­Vie’s top ex­ecs re­al­ly pull the trig­ger on a $30B M&A deal? Why, yes, ac­tu­al­ly

7 years ago

API man­u­fac­tur­er Cam­brex buys Ha­lo Phar­ma for $425M — ven­tur­ing in­to fin­ished dose man­u­fac­tur­ing

7 years ago

Sang­amo puts down $84M to ac­quire Tx­Cell, div­ing in­to CAR-Treg space, au­toim­mune dis­eases

7 years ago

Nab­bing late-stage drug, PTC ac­quires gene ther­a­py start­up Ag­ilis for $200M in cash/stock

7 years ago

By the num­bers: Se­ries A rounds are bust­ing out, plat­forms are in, M&A is down, val­u­a­tions surge and 2018 looks wicked big

7 years ago
Financing
Pharma

Ot­su­ka jumps in­to the US biotech M&A game, bag­ging Vis­ter­ra in $430M buy­out

7 years ago

Un­der pres­sure from share­hold­ers, BioCryst drops plan to merge with Idera

7 years ago

Take­da posts 'for-sale' sign on com­pa­ny's an­ces­tral home in Os­a­ka in ef­fort to fund Shire buy­out

7 years ago

Catal­ent inks $133M deal to buy Ju­niper Phar­ma­ceu­ti­cals, adding UK de­vel­op­ment ser­vices

7 years ago
Outsourcing

Ama­zon snaps up on­line phar­ma­cy start­up Pill­Pack in lat­est move to dis­rupt health­care

7 years ago

Ane­mia spe­cial­ist Ake­bia merges with Keryx on the eve of a block­buster brawl with Fi­bro­Gen

7 years ago

Take­da’s old guard los­es a key bat­tle against $62B Shire buy­out — but a much big­ger threat looms

7 years ago

Roche bags full con­trol of Foun­da­tion Med­i­cine in $2.4B fol­low-up buy­out

7 years ago
Pharma
First page Previous page 106107108109110111112 Next page Last page
A service from the Financial Times